ArticlePediatric pulmonology2026
Tobramycin Pharmacokinetics in Pediatric People With Cystic Fibrosis on Maintenance Azithromycin.
Article in Pediatric pulmonology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMany people with cystic fibrosis (PwCF) are colonized with Pseudomonas aeruginosa. Some studies have found that PwCF who use both tobramycin (TOB) and azithromycin during PEx treatment, have worse clinical outcomes, including a greater decline in percent predicted forced expiratory volume (ppFEV1) and lower odds of returning to baseline ppFEV1. The objective of this study was to compare the IV TOB elimination rate constant (Ke) between pediatric PwCF on maintenance azithromycin (mtAZM) versus those not on mtAZM.
methodsThis IRB-approved retrospective cohort study included pediatric PwCF who received IV TOB for PEx treatment from January 1, 2019-June 1, 2024.
resultsA total of 83 PwCF were included, 35 in mtAZM group and 48 in no mtAZM. Baseline characteristics were similar between both groups. The percentage of females was significantly higher in the mtAZM group (60%) versus the no mtAZM group (38%, p = 0.04). The mean TOB Ke was 0.39 h
conclusionsThis study demonstrated that mtAZM did not affect the Ke or other PK parameters of IV TOB. Despite previous reports of interactions between the two medications, our study suggests that similar TOB dosing and monitoring strategies can be used in those PwCF regardless of mtAZM use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.